Netherlands· NL-0b1d2b8cbdd4

Abacavir Accord 300 mg, filmomhulde tabletten

A abacavir product containing abacavir, registered in Netherlands by Accord Healthcare B.V.. The same ATC class is registered in 16 of our 19 countries.

ATC J05AF06

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about abacavirAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Abacavir is registered in 16 of 19 countries.

Countries holding a registration under ATC J05AF06 (abacavir), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
10 of them publish a price we can compare per daily dose

Search abacavir products by name

Abacavir · ATC J05AF06

16 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Franceprice
Icelandprice
Ireland
Netherlands
Norwayprice
Polandprice
Spainprice
Sweden
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of abacavir costs, country by country.

Normalised to the WHO defined daily dose (0.6 g), the median price runs from $3.98 in France to $9.36 in Switzerland — a ×2.3 gap.

2 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Abacavir · price per daily dose (0.6 g)

USD · FX 28 Sept 2026

CH Switzerland$9.36
FR France$3.98

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: ABACAVIR
Manufacturer: Accord Healthcare B.V.
Country: Netherlands (NL)
ATC code: J05AF06
ATC class: Abacavir
Defined daily dose: 0.6 g, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
117120

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

131 interactions on record for abacavir.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check abacavir against other medicines How interaction checks work

Abacavir · interactions on record

131 records

4 severe
23 moderate
6 minor
96 info

Most severe, free to view

LeflunomidL04AA13severe
TeriflunomidL04AA31severe
LeflunomideL04AK01severe
TeriflunomideL04AK02severe

2 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Abacavir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All abacavir products

Authorised across Europe · EMA

The same active substance is authorised in 10 EEA countries. Names it is sold under:

Spain · Abacavir Tarbis
Finland · Abacavir Accord
France · Abacavir Arrow, Abacavir Sandoz
United Kingdom (Northern Ireland) · Abacavir Milpharm, Abacavir Mylan
Iceland · Ziagen
Italy · Abacavir Mylan
Liechtenstein · Ziagen
Norway · Ziagen
Portugal · Abacavir Farmoz, Abacavir Generis
Romania · Abacavir Aurobindo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/fbb2f472-a235-4d7b-9fc1-618dbae11f54
GET /v1/drugs/fbb2f472-a235-4d7b-9fc1-618dbae11f54?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h117120_smpc.pdf",
  "strength": null,
  "atc_label": "Abacavir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg117120",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "IJZEROXIDE GEEL (E 172)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ABACAVIR"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h117120.pdf",
  "authorised_at": "2016/07/25",
  "procedure_number": "NL/H/3482/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "117120",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about abacavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console